This website uses cookies to enhance the user experience.
R

REKLIMA AS916 840 039

Research
Limited company
c/o Greve Biogass Taranrødveien 95B 3171 SEM, Norge
Services
/ Research
/ 72.110 Research and experimental development on biotechnology

REKLIMA AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

Chairman of the board
PY

Pål Yngve Smits1961

Years since formation
9 years
since Mar 3, 2016
Type
Limited company
VAT registered
Yes
Number of employees
0

Ownership

Number of shares and share classes
1,000
1 share class
Total number of shareholders
3
companies

Financials

Total operating income 2024
9,347,492
NOK
Annual total result 2024
-2,585,617
NOK
Total equity 2024
-12,330,565
NOK
Last update: Jul 2, 2025

Management

Board

NameRoleShares
PY

Pål Yngve Smits

1961

Chairman-
SH

Sigrid Hilsen

1971

Board Member-
GH

Gry Haugsnes

1974

Board Member-
TO

Thor Oscar Bolstad

1954

Board Member-

Others

NameRoleShares
S
STATSAUT. REVISOR THORMODSRUD AS
Auditor-
A
AKTIV ØKONOMISERVICE AS
Accountant-
Last update: Jun 24, 2024

Ownership

Company shareholders

NameShare classTotal number of sharesShare
L
LINDUM AS
Ordinary shares
451
45.1 %
G
GREVE BIOGASS AS
Ordinary shares
450
45 %
B
BBBL SOLUTIONS AS KONKURSBO
Ordinary shares
99
9.9 %
Last update: Jun 2, 2025

Financials

in NOK

Summary

Year2024202320222021
Total operating income
9,347,492
13,350,876
8,740,793
9,324,256
Annual Total Result
-2,585,617
-8,745,375
-3,764,947
95,935
Total assets
12,034,010
12,899,674
25,258,107
28,182,617
Total liabilities
24,364,575
22,644,621
26,257,681
25,417,243
Total equity
-12,330,565
-9,744,948
-999,573
2,765,374

P&L

Year2024202320222021
Total operating income
9,347,492
13,350,876
8,740,793
9,324,256
Total operating costs
11,347,047
21,525,660
12,108,821
8,779,187
Operating result
-1,999,555
-8,174,784
-3,368,028
545,070
Financial income/costs
-586,062
-570,590
-396,919
-449,134
Profit before tax
-2,585,617
-8,745,375
-3,764,947
95,935
Total tax & extraordinary income/cost
0
0
0
0
Annual Total Result
-2,585,617
-8,745,375
-3,764,947
95,935

Balance overview

Year2024202320222021
Total fixed assets
9,917,000
11,493,000
21,468,514
22,301,839
Total current assets
2,117,010
1,406,674
3,789,593
5,880,778
Total assets
12,034,010
12,899,674
25,258,107
28,182,617
Short term debt
7,913,577
5,760,272
9,987,822
18,205,483
Long term debt
16,450,997
16,884,349
16,269,858
7,211,760
Total liabilities
24,364,575
22,644,621
26,257,681
25,417,243
Contributed capital
2,591,000
2,591,000
2,591,000
2,669,439
Retained earnings
-14,921,565
-12,335,948
-3,590,573
95,935
Total equity
-12,330,565
-9,744,948
-999,573
2,765,374
Total equity and liabilities
12,034,010
12,899,674
25,258,107
28,182,617

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
1520
Public incorporated enterprises, owned by local government
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology